Is HALOZYME THERAPEUTICS, INC. (HALO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 26.9% / 30% | 1.8% / 30% | 5.6% / 30% | 22.74% / 5% | ✗ NOT HALAL |
| DJIM | 26.9% / 33% | 1.8% / 33% | 5.6% / 33% | 22.74% / 5% | ✗ NOT HALAL |
| MSCI | 84.8% / 33% | 5.7% / 33% | 17.5% / 33% | 22.74% / 5% | ✗ NOT HALAL |
| S&P | 26.9% / 33% | 1.8% / 33% | 5.6% / 33% | 22.74% / 5% | ✗ NOT HALAL |
| FTSE | 84.8% / 33% | 5.7% / 33% | 17.5% / 50% | 22.74% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 77.8% | |
| Operating Margin | 56.3% | |
| Net Margin | 22.7% | |
| Return on Equity (ROE) | 153.6% | |
| Return on Assets (ROA) | 22.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $652M |
| Free Cash Flow | $357M |
| Total Debt | $2.1B |
| Debt-to-Equity | 4460.2 |
| Current Ratio | 4.7 |
| Total Assets | $2.5B |
Price & Trading
| Last Close | $63.29 |
| 50-Day MA | $70.44 |
| 200-Day MA | $67.10 |
| Avg Volume | 1.9M |
| Beta | 1.0 |
|
52-Week Range
$47.50
| |
About HALOZYME THERAPEUTICS, INC. (HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is HALOZYME THERAPEUTICS, INC. (HALO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), HALOZYME THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is HALOZYME THERAPEUTICS, INC.'s debt ratio?
HALOZYME THERAPEUTICS, INC.'s debt ratio is 26.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 84.8%.
What are HALOZYME THERAPEUTICS, INC.'s key financial metrics?
HALOZYME THERAPEUTICS, INC. has a market capitalization of $7.3B, trailing P/E ratio of 24.1, and revenue of $1.4B. The company maintains a gross margin of 77.8% and a net margin of 22.7%. Return on equity stands at 153.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.